These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 31769890)

  • 1. Peroxisome proliferator-activated receptor gamma controls prostate cancer cell growth through AR-dependent and independent mechanisms.
    Elix CC; Salgia MM; Otto-Duessel M; Copeland BT; Yoo C; Lee M; Tew BY; Ann D; Pal SK; Jones JO
    Prostate; 2020 Feb; 80(2):162-172. PubMed ID: 31769890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Androgen Receptor Regulates PPARγ Expression and Activity in Human Prostate Cancer Cells.
    Olokpa E; Bolden A; Stewart LV
    J Cell Physiol; 2016 Dec; 231(12):2664-72. PubMed ID: 26945682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PPARγ ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells.
    Moss PE; Lyles BE; Stewart LV
    Exp Cell Res; 2010 Dec; 316(20):3478-88. PubMed ID: 20932825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of peroxisome proliferator-activated receptor gamma in prostate cancer.
    Elix C; Pal SK; Jones JO
    Asian J Androl; 2018; 20(3):238-243. PubMed ID: 28597850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARγ/MMP-9 signals.
    Deng G; Wang R; Sun Y; Huang CP; Yeh S; You B; Feng C; Li G; Ma S; Chang C
    Cell Death Differ; 2021 Jul; 28(7):2145-2159. PubMed ID: 34127806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin K epoxide reductase regulation of androgen receptor activity.
    Tew BY; Hong TB; Otto-Duessel M; Elix C; Castro E; He M; Wu X; Pal SK; Kalkum M; Jones JO
    Oncotarget; 2017 Feb; 8(8):13818-13831. PubMed ID: 28099154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PPARgamma inhibitors reduce tubulin protein levels by a PPARgamma, PPARdelta and proteasome-independent mechanism, resulting in cell cycle arrest, apoptosis and reduced metastasis of colorectal carcinoma cells.
    Schaefer KL; Takahashi H; Morales VM; Harris G; Barton S; Osawa E; Nakajima A; Saubermann LJ
    Int J Cancer; 2007 Feb; 120(3):702-13. PubMed ID: 17096328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidative stress in peroxisomes induced by androgen receptor inhibition through peroxisome proliferator-activated receptor promotes enzalutamide resistance in prostate cancer.
    Shiota M; Ushijima M; Tsukahara S; Nagakawa S; Okada T; Tanegashima T; Kobayashi S; Matsumoto T; Eto M
    Free Radic Biol Med; 2024 Aug; 221():81-88. PubMed ID: 38762061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma.
    Kim KR; Choi HN; Lee HJ; Baek HA; Park HS; Jang KY; Chung MJ; Moon WS
    Oncol Rep; 2007 Oct; 18(4):825-32. PubMed ID: 17786342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
    Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peroxisome proliferator-activated receptor gamma-independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation.
    Yang CC; Wang YC; Wei S; Lin LF; Chen CS; Lee CC; Lin CC; Chen CS
    Cancer Res; 2007 Apr; 67(7):3229-38. PubMed ID: 17409431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tanshinones from Chinese medicinal herb Danshen (Salvia miltiorrhiza Bunge) suppress prostate cancer growth and androgen receptor signaling.
    Zhang Y; Won SH; Jiang C; Lee HJ; Jeong SJ; Lee EO; Zhang J; Ye M; Kim SH; Lü J
    Pharm Res; 2012 Jun; 29(6):1595-608. PubMed ID: 22281759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-O-methylhonokiol, a PPARγ agonist, inhibits prostate tumour growth: p21-mediated suppression of NF-κB activity.
    Lee NJ; Oh JH; Ban JO; Shim JH; Lee HP; Jung JK; Ahn BW; Yoon DY; Han SB; Ham YW; Hong JT
    Br J Pharmacol; 2013 Mar; 168(5):1133-45. PubMed ID: 23043610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.
    Isikbay M; Otto K; Kregel S; Kach J; Cai Y; Vander Griend DJ; Conzen SD; Szmulewitz RZ
    Horm Cancer; 2014 Apr; 5(2):72-89. PubMed ID: 24615402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostaglandin 15d-PGJ(2) inhibits androgen receptor signaling in prostate cancer cells.
    Kaikkonen S; Paakinaho V; Sutinen P; Levonen AL; Palvimo JJ
    Mol Endocrinol; 2013 Feb; 27(2):212-23. PubMed ID: 23192983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARgamma-dependent and PPARgamma-independent pathways.
    Lyles BE; Akinyeke TO; Moss PE; Stewart LV
    Cell Cycle; 2009 Jan; 8(2):268-77. PubMed ID: 19164938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T0070907, a PPAR γ inhibitor, induced G2/M arrest enhances the effect of radiation in human cervical cancer cells through mitotic catastrophe.
    An Z; Muthusami S; Yu JR; Park WY
    Reprod Sci; 2014 Nov; 21(11):1352-61. PubMed ID: 24642720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of peroxisome proliferator-activated receptor gamma activity suppresses pancreatic cancer cell motility.
    Nakajima A; Tomimoto A; Fujita K; Sugiyama M; Takahashi H; Ikeda I; Hosono K; Endo H; Yoneda K; Iida H; Inamori M; Kubota K; Saito S; Nakajima N; Wada K; Nagashima Y; Nakagama H
    Cancer Sci; 2008 Oct; 99(10):1892-900. PubMed ID: 19016747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoisoliquiritin exerts tumor suppressive effects on prostate cancer by repressing androgen receptor activity.
    Chen C; Shao R; Li B; Zhai Y; Wang T; Li X; Miao L; Huang J; Liu R; Liu E; Zhu Y; Gao X; Zhang H; Wang Y
    Phytomedicine; 2021 May; 85():153514. PubMed ID: 33676083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes inhibit growth, induce apoptosis, and decrease the androgen receptor in LNCaP prostate cancer cells through peroxisome proliferator-activated receptor gamma-independent pathways.
    Chintharlapalli S; Papineni S; Safe S
    Mol Pharmacol; 2007 Feb; 71(2):558-69. PubMed ID: 17093136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.